| Predicted Trait | |
| Reported Trait | Breast carcinoma |
| Mapped Trait(s) | breast carcinoma (EFO_0000305) |
| Score Construction | |
| PGS Name | SBayesRC |
| Development Method | |
| Name | SBayesRC |
| Parameters | SBayesRC extends SBayesR by incorporating functional annotations, enabling the joint analysis of all common SNPs across the genome. It utilises a multicomponent annotation-dependent mixture prior to more accurately model the distribution of SNP effects, allowing it to estimate both annotation parameters and SNP effects. SBayesRC does not require a tuning cohort. |
| Variants | |
| Original Genome Build | GRCh37 |
| Number of Variants | 5,387,266 |
| Effect Weight Type | beta |
| PGS Source | |
| PGS Catalog Publication (PGP) ID | PGP000771 |
| Citation (link to publication) | Tanha HM et al. Eur J Hum Genet (2026) |
| Ancestry Distribution | |
| Source of Variant Associations (GWAS) | European: 100% 247,173 individuals (100%) |
| PGS Evaluation | European: 60% African: 20% South Asian: 20% 5 Sample Sets |
| Study Identifiers | Sample Numbers | Sample Ancestry | Cohort(s) |
|---|---|---|---|
GWAS Catalog: GCST010098 Europe PMC: 32424353 |
247,173 individuals | European | BCAC |
|
PGS Performance Metric ID (PPM) |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
|---|---|---|---|---|---|---|---|---|
| PPM023141 | PSS012140| European Ancestry| 212,360 individuals |
PGP000771 | Tanha HM et al. Eur J Hum Genet (2026) |
Reported Trait: Breast Carcinoma | — | AUROC: 0.639 [0.63, 0.649] | — | - | — |
| PPM023146 | PSS012138| European Ancestry| 8,291 individuals |
PGP000771 | Tanha HM et al. Eur J Hum Genet (2026) |
Reported Trait: Breast Carcinoma | — | AUROC: 0.647 [0.607, 0.686] | — | - | — |
| PPM023151 | PSS012137| European Ancestry| 2,654 individuals |
PGP000771 | Tanha HM et al. Eur J Hum Genet (2026) |
Reported Trait: Breast Carcinoma | — | AUROC: 0.727 [0.692, 0.762] | — | - | — |
| PPM023156 | PSS012139| African Ancestry| 4,427 individuals |
PGP000771 | Tanha HM et al. Eur J Hum Genet (2026) |
Reported Trait: Breast Carcinoma | — | AUROC: 0.605 [0.483, 0.727] | — | - | — |
| PPM023161 | PSS012141| South Asian Ancestry| 4,435 individuals |
PGP000771 | Tanha HM et al. Eur J Hum Genet (2026) |
Reported Trait: Breast Carcinoma | — | AUROC: 0.693 [0.614, 0.773] | — | - | — |
| PPM023166 | PSS012140| European Ancestry| 212,360 individuals |
PGP000771 | Tanha HM et al. Eur J Hum Genet (2026) |
Reported Trait: Breast Carcinoma | — | AUROC: 0.644 [0.634, 0.654] | — | Age-specific absolute risk adjusted by PGS relative risk | — |
| PPM023171 | PSS012138| European Ancestry| 8,291 individuals |
PGP000771 | Tanha HM et al. Eur J Hum Genet (2026) |
Reported Trait: Breast Carcinoma | — | AUROC: 0.645 [0.605, 0.685] | — | Age-specific absolute risk adjusted by PGS relative risk | — |
| PPM023176 | PSS012137| European Ancestry| 2,654 individuals |
PGP000771 | Tanha HM et al. Eur J Hum Genet (2026) |
Reported Trait: Breast Carcinoma | — | AUROC: 0.713 [0.678, 0.748] | — | Age-specific absolute risk adjusted by PGS relative risk | — |
| PPM023181 | PSS012139| African Ancestry| 4,427 individuals |
PGP000771 | Tanha HM et al. Eur J Hum Genet (2026) |
Reported Trait: Breast Carcinoma | — | AUROC: 0.585 [0.485, 0.685] | — | Age-specific absolute risk adjusted by PGS relative risk | — |
| PPM023186 | PSS012141| South Asian Ancestry| 4,435 individuals |
PGP000771 | Tanha HM et al. Eur J Hum Genet (2026) |
Reported Trait: Breast Carcinoma | — | AUROC: 0.647 [0.564, 0.731] | — | Age-specific absolute risk adjusted by PGS relative risk | — |
|
PGS Sample Set ID (PSS) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
|---|---|---|---|---|---|---|---|---|
| PSS012137 | Linked cancer registry records were used to identify females diagnosed with invasive breast cancer (ICD-10 code: C50; ICD-9 code: 174) within five years of prediction baseline. | — | [ ,
0.0 % Male samples |
European | PC1-PC4 values ±3s.d. from the 1000G European cluster | MCCS | MCCS had a case/sub-cohort design, leading to a higher proportion of cases | |
| PSS012138 | Linked cancer registry records were used to identify females diagnosed with invasive breast cancer (ICD-10 code: C50; ICD-9 code: 174) within five years of prediction baseline. | — | [ ,
0.0 % Male samples |
European | PC1-PC4 values ±3s.d. from the 1000G European cluster | QSKIN | — | |
| PSS012139 | Linked cancer registry records were used to identify females diagnosed with invasive breast cancer (ICD-10 code: C50; ICD-9 code: 174) within five years of prediction baseline. | — | [ ,
0.0 % Male samples |
African American or Afro-Caribbean | AFR individuals were identified by PC1-PC4 from 1000G and k-means clustering. | UKB | — | |
| PSS012140 | Linked cancer registry records were used to identify females diagnosed with invasive breast cancer (ICD-10 code: C50; ICD-9 code: 174) within five years of prediction baseline. | — | [ ,
0.0 % Male samples |
European | EUR individuals were identified by PC1-PC4 from 1000G and k-means clustering. | UKB | — | |
| PSS012141 | Linked cancer registry records were used to identify females diagnosed with invasive breast cancer (ICD-10 code: C50; ICD-9 code: 174) within five years of prediction baseline. | — | [ ,
0.0 % Male samples |
South Asian | SAS individuals were identified by PC1-PC4 from 1000G and k-means clustering. | UKB | — |